living medicine News
-
Redbiotec expands its Scientific Advisory Board with the appointment of Prof. Dr. Dr. Christoph U. Schoen
Redbiotec AG, a pioneer in living medicines, is pleased to announce the addition of Professor Christoph U. Schoen, MD, PhD to its Scientific Advisory Board. Dr. Schoen is a Professor of Medical Microbiology at the University of Würzburg, and the Head of the Laboratory for Diagnostic Microbiology, Institute for Hygiene and Microbiology. He is an expert in clinical microbiology, with 20 years ...
By Redbiotec AG
-
Redbiotec Signs Collaboration Agreement with Large-Cap Pharma to Develop Targeted Living Medicines
Redbiotec AG has entered into a research collaboration and exclusive option agreement with a large-cap pharmaceutical company. The collaboration will leverage Redbiotec’s proprietary bacteria platform BRISPR® for the targeted delivery of gene therapy cargos from the partner. “Redbiotec’s bacteria hold great potential in overcoming the delivery hurdles faced by conventional ...
By Redbiotec AG
-
Gene therapy expert Dr. Michele Calos joins the Scientific Advisory Board of Redbiotec
Redbiotec AG, a pioneer in living medicines, further expands its Scientific Advisory Board with the appointment of Professor Michele Calos, PhD. Dr. Calos is a Professor of Genetics at Stanford University. A recent President of the American Society of Gene and Cell Therapy (ASGCT), Dr. Calos brings over four decades of research experience in genetics and genomic modification and has been ...
By Redbiotec AG
-
Pathway to Solve "Aging Population Syndrome", New Hope Has Been Delivered at TEDx Event
CHENGDU, China, Sept. 7, 2017 /PRNewswire/ -- Aging and related diseases are problems we have to face. Recently, Dr. Y. James Kang, CEO/CSO of Revotek and a pathfinder in Regenerative Medicine, delivered a talk entitled "Transforming Disease-based Medication to Personalized Healthcare" at the TEDx event in Chengdu, China. He unveiled techniques that would improve the quality of life for 2 billion ...
-
Thermo Fisher Scientific Sponsors Precision Medicine Summit in China
Thermo Fisher Scientific, the world leader in serving science, today sponsored the first China-U.S. Precision Medicine Summit, along with co-hosts CEO Roundtable on Cancer, China Academy of Medical Sciences and Peking Union Medical College. The Summit convened more than 400 leaders from across government, academia and industry to promote partnership and collaboration that will lead to advances in ...
-
Amanda Kay Appointed Chief Business Officer of Deep Genomics, Tasked with Overseeing Expansion of Partnership Strategy
Company also announces appointment of Tom Hughes, Boston-based biotech builder and CEO of Navitor Pharmaceuticals, to board of directors. Company now advancing multiple programs in neurodevelopmental, neurodegenerative and metabolic disorders. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Amanda Kay, Ph.D., to the newly ...
-
Scion Co-Sponsors Cassi II Breast Biopsy Device Ultrasound Training for Chinese Physicians
During the week of Monday, April 30 – Saturday, May 5, 2012, seven physicians from China will train with internationally distinguished interventional radiologist Ken Tomkovich, MD, director of breast imaging and interventional radiology at CentraState Medical Center and affiliated with Freehold Radiology Group. The training will cover the latest imaging and interventional radiology ...
-
BlueRock Therapeutics Announces New Board Chair, New President and CEO
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer?AG, announced?today?that Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth Ettenberg, Ph.D., will assume the role of President and CEO. BlueRock will continue in its mission ...
-
Onegene Biotechnology announced $33.5 million series B financing completed
Onegene Biotechnology is pioneering multi-target therapeutics to create breakthrough medicines that will transform the lives of people with complex and chronic diseases. Onegene's platform can generate highly potent tri- or tetra-specific protein-based drugs using different therapeutic modalities. With unprecedented design flexibility and optimal physical properties, Onegene Biotechnology is ...
-
Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company focused on the development of regenerative medicines to save lives, announced today that the Biomedical Advanced Research and Development Authority (BARDA) part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services executed options to add $10.4 ...
-
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this ...
-
Virica Biotech to be Showcased in Xtalks Webinar: Process Intensification in AAV Gene Therapy
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. AAV vectors are critical to gene therapy development. These vectors are the delivery ...
-
Healx and Ovid Therapeutics Enter Strategic Partnership
Ovid Therapeutics (NASDAQ:OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, and Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced that Healx has secured from Ovid an exclusive option to license rights to develop and ...
By Healx Ltd.
-
VIDA receives 510(k) clearance for deep learning-based enhancements to its LungPrint solution
VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for enhancements to its LungPrint solution, including automated deep learning-based lung and lobe segmentation algorithms. This clearance further validates the quality and clinical efficacy of the ...
-
Citrine medicine and Sinopharm group announce strategic partnership to broaden and accelerate access to rare disease drugs in china
Collaboration to focus on establishing supply chain and securing distribution channels for delivering rare disease therapies to patients across China BOSTON, Mass. and SHANGHAI, China, April 19, 2021 – Citrine Medicine, a China-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the ...
-
Novo Nordisk to Acquire Dicerna
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a premium of ...
-
INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results
INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss ...
-
Robocath successfully carries out Europe’s first remote robotic-assisted coronary angioplasty
Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces the successful completion of the first remote robotic-assisted coronary angioplasty in Europe. The procedure was carried out by Prof. Eric Durand and Prof. Rémi Sabatier at the Rouen Medical Training Center and Caen University Hospital in ...
By Robocath
-
AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics. Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene ...
By Bayer AG
-
Visit of His Majesty the King of the Belgians Philippe and Her Majesty the Queen of the Belgians Mathilde to Afrigen Biologics
HM King Philippe and HM Queen Mathilde, currently on a state visit to South Africa until March 27, visited the Afrigen Biologics facility in Cape Town to learn more about how two Belgian companies, Univercells and etherna, are supporting the development of the first African- developed mRNA COVID-19 vaccine. The King and The Queen are accompanied by five ministers of federal and regional ...
By eTheRNA
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you